Biotech Startups

Step Pharma develops oral cancer drugs that inhibit the enzyme cytidine triphosphate synthase 1 (CTPS1), with its lead therapeutic dencatistat in clinical development for lymphoma, solid tumors, and essential thrombocythaemia.

5 investors

Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients. The company was founded by cancer biology researchers and focuses on discovering and developing precision cancer medicines.

5 investors

Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions. The company focuses on drug development and translational biology to address unmet medical needs.

5 investors

Synthace provides a software platform for experimental design and lab automation, enabling researchers to run Design of Experiments (DOE) workflows across multiple automated laboratory instruments and devices.

5 investors

Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target. Its lead program targets TAG72, a non-internalizing marker expressed in difficult-to-treat solid tumors, aiming to expand ADC target scope and therapeutic window.

5 investors

Clinical-stage biotech developing cell therapy products for transplant and autoimmune conditions

5 investors

Tamarind provides a computational platform for protein and molecular engineering, offering AI and physics-based tools to design antibodies, peptides, enzymes, and small molecules. The platform integrates state-of-the-art published tools like AlphaFold and RFdiffusion through a user-friendly interface for life sciences companies.

5 investors

Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors. The company focuses on expanding access to precision cancer therapies for patients.

5 investors

Tarsus is a biopharmaceutical company focused on developing and delivering medicines that target the root cause of serious diseases with high unmet need, including eye conditions. Its treatment areas include Demodex blepharitis, and it works closely with eye care professionals and patients.

5 investors

Taxa develops probiotic skincare products that target the skin microbiome, including a single-application deodorant cream that lasts one week. The company makes shelf-stable probiotic creams using natural ingredients such as mango butter and sunflower extract.

5 investors

Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment. It uses its Adenovo platform to screen large libraries of adenovirus variants in human systems to identify therapeutic candidates, with THEO-260 as its lead programme.

5 investors

Torigen provides cancer diagnostics and personalized immunotherapy for veterinary patients, partnering with veterinary clinics to offer specialty pathology and autologous cancer vaccines made from a patient's own tumor tissue. Its approach targets tumor-specific antigens to treat cancer in pets.

5 investors

Trace Genomics, now part of Miraterra, provides soil analysis and genomic sequencing to give growers and agronomists insights on nutrients and pathogens across more than 70 crops and 225+ pathogens. Its TraceCOMPLETE product portfolio (including TracePHOS, TraceN, TraceCHEM, and TraceCARBON) supports seed selection, treatment, and soil management decisions in agriculture.

5 investors

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc. It is advancing the treatment for patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

5 investors

5 investors

Twig uses artificial intelligence and biology to design novel microbes for ingredient production. The company develops bioengineered microbes that generate high-yield, cost-effective ingredients for industrial applications, serving the global ingredients and manufacturing sectors.

5 investors

TwoStep Therapeutics is a Stanford spinout developing targeted cancer therapies, including peptide-based drug conjugates and radioligand programs built on a tumor-targeting peptide platform. The company is advancing a preclinical pipeline toward a first clinical trial planned for the second half of 2026.

5 investors

Tybrhealth develops the B3 GEL™ System, a protective gel applied during tendon and ligament repair surgery to reduce post-operative scar formation and preserve tissue mobility. The product is marketed to surgeons seeking to improve functional outcomes for patients recovering from tendon repair procedures.

5 investors

Uncaged Innovations is a biomaterials company that makes grain- and plant-based leather alternatives using its proprietary BioFuze platform, which replicates the collagen structure of animal leather. Its Elevate material is a tanning-free, scalable leather substitute aimed at industries seeking sustainable, luxury-quality materials.

5 investors

Unicorn is building technology to automate biology, developed by a team of scientists and engineers.

5 investors

Unravel Bio uses computational drug discovery and advanced animal models to accelerate pharmaceutical development with lower cost and risk. The company serves biopharma partners, foundations, and patients seeking treatments for rare and complex diseases.

5 investors

Upstream Biotechnology develops seed-based crop technologies that enhance plant immunity and resilience using RNA-based SwitchBlade platform. The company translates foundational plant-immunity science into commercial agricultural solutions for seed-company partnerships.

5 investors

Varinos develops and provides genetic testing services applying genome technology, including a uterine microbiome (endometrial flora) test used in fertility and reproductive medicine. The company serves patients and clinics addressing infertility.

5 investors

VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings. The company focuses on advancing coagulation therapy for patients taking this class of blood thinners.

5 investors